| 產(chǎn)品名稱 |
H21F8-1 |
| 商品貨號 |
B164529 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
hepatitis |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with P3-NSI/1Ag4-1 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against hepatitis B virus surface antigen (HBsAg) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against hepatitis B virus surface antigen (HBsAg) |
| Comments |
Animals were immunized with hepatitis B virus surface antigen. Spleen cells were fused with P3-NSI/1Ag4-1 myeloma cells. |
| Complete Growth Medium |
Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgM |
| Name of Depositor |
Massachusetts General Hospital |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Wands JR, Zurawski VR Jr.. Process for producing antibodies to hepatitis virus and cell lines therefor. US Patent 4,271,145 dated Jun 2 1981
|
